Yoichi Ajioka

Publications (2)3.56 Total impact

• Source

  Available from: Tatsuo Kanda

  Article: Expression of receptor tyrosine kinases in esophageal carcinosarcoma.

  Akihiko Sano, Shinji Sakurai, Hiroyuki Kato, Shigemasa Suzuki, Takehiko Yokobori, Makoto Sakai, Naritaka Tanaka, Takanori Inose, Makoto Sohda, Masanobu Nakajima, Yasuyuki Fukai, Tatsuya Miyazaki, Hitoshi Ojima, Yoshinori Hosoya, Takehiko Enomoto, Tatsuo Kanda, Yoichi Ajioka, Hiroyuki Kuwano
  [show abstract] [hide abstract]
  ABSTRACT: Esophageal carcinosarcoma (ECS) is a rare malignant neoplasm associated with a poor patient prognosis. It is characterized by the presence of both malignant epithelial and mesenchymal components. Molecular-targeted therapy of several receptor tyrosine kinases (RTKs) has been reported to be effective in the treatment of various malignant tumors, including carcinosarcoma of several organs. This study aimed to assess the therapeutic potential of targeting RTKs in ECS. Overexpression of RTKs was assessed in 21 ECS cases by immunohistochemistry (IHC). Positively stained cases were further examined for RTK gene mutations and amplifications by direct sequencing analysis and fluorescence in situ hybridization. In epithelial components, KIT, platelet-derived growth factor receptor (PDGFR)A, PDGFRB, MET, epidermal growth factor receptor (EGFR) and HER-2 were overexpressed in 1 (4.8%), 1 (4.8%), 0 (0%), 11 (52.4%), 13 (61.9%) and 2 (9.5%) cases, respectively. In the mesenchymal components the corresponding numbers of cases were 2 (9.5%), 2 (9.5%), 0 (0%), 12 (57.1%), 11 (52.4%) and 0 (0%). No mutations in the c-kit, PDGFRA and c-met genes were found. Among 19 EGFR-positive tumors, 2 had EGFR missense mutations (T790A, exon 20) only in the mesenchymal component. Gene amplification or high polysomy of c-kit, PDGFRA, c-met and EGFR was observed in 1 (33.3%), 0 (0%), 3 (18.8%) and 10 (52.6%) cases, respectively. In conclusion, various RTKs, particularly MET and EGFR were overexpressed in ECSs suggesting that molecular-targeted therapies directed to MET, EGFR or other RTKs may be effective in inhibiting the growth or progression of the epithelial and/or mesenchymal component of ECS.
  Oncology Reports 03/2013; · 1.84 Impact Factor
• Article: Clinicopathological and immunohistochemical characteristics of esophageal carcinosarcoma.

  Akihiko Sano, Shinji Sakurai, Hiroyuki Kato, Makoto Sakai, Naritaka Tanaka, Takanori Inose, Kana Saito, Makoto Sohda, Masanobu Nakajima, Kazuha Sakamoto, Takaaki Sano, Yoshinori Hosoya, Takehiko Enomoto, Tatsuo Kanda, Yoichi Ajioka, Tetsunari Oyama, Hiroyuki Kuwano
  [show abstract] [hide abstract]
  ABSTRACT: Esophageal carcinosarcoma is a very rare neoplasm and its clinicopathological characteristics and the prognostic factors that influence the clinical outcome of the patient remain a matter of controversy. Twenty patients with esophageal carcinosarcoma were referred to our institutions. Tissue blocks were reviewed and sections containing both carcinomatous and sarcomatous components were stained for epithelial and mesenchymal markers and a proliferating cell marker. The prognosis of the esophageal carcinosarcoma patients was compared with 142 cases of esophageal squamous cell carcinoma. In the carcinomatous component, the expression of cytokeratin, epithelial membrane antigen, vimentin, smooth muscle actin, and S100 were detected in 20, 20, 1, 1, and 1 case, respectively, whereas in the sarcomatous component, expression of these were detected in 4, 2, 18, 15, and 3 cases, respectively. The Ki-67 labeling index of carcinomatous and sarcomatous components was 35.5% and 41.8%, respectively. The 5-year survival rate was not statistically different between squamous cell carcinoma and carcinosarcoma (p=0.219). However, for T1 cases only, carcinosarcoma patients had statistically poorer prognosis than did squamous cell carcinoma patients (p=0.008). The sarcomatous component shows various histological and immunohistochemical forms. In comparison with squamous cell carcinoma patients, carcinosarcoma patients had poorer prognosis amongst the T1 cases. For the treatment of esophageal carcinosarcoma, it is important to monitor lymph nodes and be watchful for hematogenous metastasis, as in cases of esophageal squamous cell carcinoma.
  Anticancer research 09/2009; 29(8):3375-80. · 1.73 Impact Factor